14-03_OGI

First to invest

November 25, 2015

As leaders in identifying the potential for, and investing in the development of early-stage genomics and proteomics discoveries, we are often the first to invest in winning ideas that will be attractive to later-stage investors for commercialization of the technology.

Through our demand-pull model, along with our affiliation with Genome Canada, we’ve successfully identified, nurtured and de-risked these ideas, helping the following companies to take the next step and secure larger investments from our downstream partners.

  • ArcticDX
  • Encycle Therapeutics
  • Northern Biologics
  • DVS Sciences
  • Xagenic
  • Rna Diagnostics
  • Fio
  • Deep Genomics
  • ProMIS Neurosciences

In addition, our early seed funding program exhibits an outstanding success rate. Five out of seven of the companies we have given funding to between 2005 and 2012 have generated revenue or raised follow-on capital. Learn more about the upcoming PBDF funding and other opportunities and contact our business leads to find out how we can help you take your discovery to the next level.